Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Next Previous
Search
Trial Profile

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Invikafusp alfa (Primary)
  • Indications Anal cancer; Cervical cancer; Colorectal cancer; Merkel cell carcinoma; Non-small cell lung cancer; Oropharyngeal cancer; Ovarian cancer; Penile cancer; Prostate cancer; Solid tumours; Triple negative breast cancer; Vulval disorders; Vulvovaginal cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms START-001
  • Sponsors Marengo Therapeutics

Most Recent Events

  • 29 Apr 2025 Results presented in the Marengo Therapeutics Media Release.
  • 29 Apr 2025 According to a Marengo Therapeutics media release, company presented result data from this study at the American Association for Cancer Research (AACR) Annual Meeting 2025.
  • 25 Apr 2025 According to a Marengo Therapeutics media release, company will present data reporting updated clinical and translational findings from this study in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top